• Currently, how confident are you in your ability to:

    1 = not confident, 2 = somewhat confident, 3 = confident, 4 = very confident, 5 = extremely confident, 6= Not applicable to me

  •    
  •    

  • Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with non-small cell lung cancer

    1 = Never, 2 = Not often, 3 = Sometimes, 4 = Often, 5 = Always, 6= Not applicable to me

  •    
  •    
  • 1. Uncommon EGFR mutations have been defined in more than one way including the exon 18 G719X, exon 20 S768I, and exon 21 L861Q. Which is recommended as the standard of care for patients with uncommon EGFR mutations?*
  • 2. In the Osimertinib CNS Activity, the first generation of EGFR TKI’s developed brain metastases. When looking at the Cumulative Incidence of CNS Progression, how can one be sure to increase the quality of life of patients?*
  • 3. Instead of using a “one size fits all” approach to non-small cell lung cancer patient care, how is it possible to individualize treatment?*
  • 4. When simply adding pembrolizumab to carboplatin or cisplatin plus pemetrexed, the following clinical parameters will be affected:*
  • 5. When offering paclitaxel combination to patients with EGFR or ALK it is important to keep in mind the toxicities when prescribing. These toxicities include:*
  • 1. Uncommon EGFR mutations have been defined in more than one way including the exon 18 G719X, exon 20 S768I, and exon 21 L861Q. Which is recommended as the standard of care for patients with uncommon EGFR mutations?*
  • 2. In the Osimertinib CNS Activity, the first generation of EGFR TKI’s developed brain metastases. When looking at the Cumulative Incidence of CNS Progression, how can one be sure to increase the quality of life of patients?*
  • 3. Instead of using a “one size fits all” approach to non-small cell lung cancer patient care, how is it possible to individualize treatment?*
  • 4. When simply adding pembrolizumab to carboplatin or cisplatin plus pemetrexed, the following clinical parameters will be affected:*
  • 5. When offering paclitaxel combination to patients with EGFR or ALK it is important to keep in mind the toxicities when prescribing. These toxicities include:*

  • You need at least a 70% to Continue

  • You have passed the Post-Test

    Complete the following Evaluation to receive your Certificate

  • 1. How many patients do you currently see each month regarding non-small cell lung cancer?

  • 2. Using the scale below, please rate this CE activity:

    1 = poor, 2 = fair, 3 = good, 4 = very good, 5 = excellent

  •    
  •    
  •    

  • 3. To what extent do you agree that the learning objectives were met:

    1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, 5 = strongly agree

  •    
  •    

  • 4. After participating in this activity, how confident are you in your ability to:

    1 = not confident, 2 = somewhat confident, 3 = confident, 4 = very confident, 5 = extremely confident, Leave Blank = not applicable to me

  •    
  •    
  • 5. As a result of participating in this activity, I will consider current clinical advances to improve outcomes in patients with non-small cell lung cancer
  • 6. Has this education enhanced your role as a member of the healthcare team?
  • 7. Do you feel this activity was fair balanced and free of commercial bias?

  • 8. Please indicate how often you NOW PLAN to use the following strategies based on your participation in this CE activity

    1 = Never, 2 = Not often, 3 = Sometimes, 4 = Often, 5 = Always, Leave Blank= Not applicable to me

  •    
  •    
  • Should be Empty: